SUMMARY  

• The company cannot recommend any practices, procedures, or usage that deviate from the approved labeling.
• Case reports evaluating the use of TREMFYA in patients with psoriasis (PsO) and comorbid multiple sclerosis (MS) are summarized below.¹

CLINICAL STUDIES

Case Reports

Hsieh et al (2025)¹ reported 2 patients with PsO who were managed with TREMFYA without alteration of MS activity.

Case 1

• A 44-year-old woman developed PsO at 18 years of age.
• At the age of 31 years, she had visual disturbance and was referred to neurologists.
• Brain magnetic resonance imaging (MRI) revealed features of MS. The baseline Expanded Disability Status Scale (EDSS) was 3.5, and a re-evaluation after systemic steroid use in 2011-2012 demonstrated a decreased EDSS score of 3.0 in early 2012.
• From February 2012 to October 2019, the patient used ustekinumab 45 mg, and the same was replaced with TREMFYA until August 2024.
• The patient’s baseline Psoriasis Area and Severity Index (PASI) score was 4.6, and after the initiation of ustekinumab and TREMFYA, it improved to 1.6-2.4, with a few refractory lesions on the legs.
• In 2012-2019, the patient had mild occasional nystagmus that resolved spontaneously after rest, with an EDSS score of 1.0-3.0.
• As the patient’s MS disease activity was stable with an EDSS score of 1.0, she did not return to the neurology clinic since 2019.

Case 2

• A 70-year-old female visited the neurology clinic at the age of 46 years for dizziness, vomiting, and left-sided weakness. MRI of the brain revealed features of MS.
• Treatment with interferon-β (IFN-β) showed an improvement in neurological symptoms, with an EDSS score of 1.0-2.0 in 2009-2019. She had mild fatigue and emotional disturbance occasionally. However, IFN-β treatment aggravated the patient’s PsO, with multiple new lesions induced at the injection sites and her baseline PASI score of 1.4 increasing to 7.
• From 2007 to 2019, the patient was treated with methotrexate 7.5 mg/week and topical therapies. As the patient had refractory lesions on the scalp and nail, ustekinumab 45 mg was initiated in 2019, which was later replaced with TREMFYA from January 2020 to January 2022.
• From 2019 onwards, the patient’s EDSS score remained 1.0.

Literature Search

A literature search of MEDLINE^®, EMBASE^®, BIOSIS Previews^®, and DERWENT^® (and/or other resources, including internal/external databases) was conducted on 20 January 2026.